Drugs, bugs & cancer…
A strong week for cancer science, with new findings covering treatment personalisation, the biology of how cancer develops and can be disrupted, sustainable drug production, and the role of gut health in cancer risk.
Predicting who will benefit from breast cancer immunotherapy
Not everyone with breast cancer responds to immunotherapy — treatments that work by boosting the body's own immune system to fight the disease. A new study of 160 people with breast cancer has made progress towards predicting in advance who is likely to benefit. Researchers found 19 genes in patients' immune cells that play a key role in determining whether those cells will respond to a particular type of immunotherapy. They also found that patients whose immune cells were more genetically varied before treatment started were more likely to respond well. By combining the 19-gene signature with this measure of diversity, they created a single blood-based indicator — a biomarker — that could one day help doctors tailor treatment far more precisely. This is still a research finding, but it is a meaningful step towards more personalised cancer care.
Read more: https://doi.org/10.1126/scitranslmed.aec2358
How cells self-destruct and what it means for cancer
Healthy cells have built-in self-destruct mechanisms that activate when something goes wrong inside them. One of these is called ferroptosis — a process in which reactive iron molecules build up and trigger the cell's death. This mechanism helps keep cancer in check naturally, because cells behaving abnormally can be eliminated this way. Researchers have now discovered that a natural substance produced in the body called spermine can block this process by trapping iron — effectively switching the self-destruct off. Understanding what turns ferroptosis on or off matters greatly for cancer treatment, because it opens up the possibility of drugs that could restore this protective cell-death pathway in cancer cells that have found ways to evade it. This is early-stage science, but it adds meaningfully to our understanding of how cancer progresses and how it might be disrupted.
Read more: https://www.nature.com/articles/d41586-026-01802-3
Producing cancer drugs more sustainably
Two important cancer drugs — etoposide and teniposide, used in treating certain lung cancers, leukaemias, and other cancers — are currently derived from plants that are difficult to cultivate at scale and are vulnerable to overharvesting in the wild. Scientists have now developed a way to produce these drugs in yeast, using a specially designed biological manufacturing process. This kind of laboratory-based production could help ensure a more reliable and sustainable supply of medicines that patients depend on, and may eventually help reduce costs. It is a less headline-grabbing development, but a genuinely important one for the practicalities of keeping essential treatments available. Read more: https://doi.org/10.1126/science.aef5438
Gut bacteria and colorectal cancer
The bacteria living in our gut — known as the gut microbiota — play a vital role in our health. When this balance is disrupted, a condition called dysbiosis can occur, which has been linked to a range of conditions including colorectal cancer (cancer of the bowel). New research has looked more closely at what actually changes in the gut when dysbiosis occurs. Scientists found that the bacterial community becomes simplified — fewer species dominate, and they tend to cooperate in ways that look very different from a healthy gut, where bacteria mostly compete with one another. Understanding these mechanics more precisely could eventually point to new ways of reducing cancer risk or supporting treatment. This is early research, but it forms part of a growing body of evidence connecting gut health to cancer.
Read more: https://doi.org/10.1126/science.ady1729
As ever, if any of these findings feel relevant to your own situation or someone you care for, please do speak with your clinical team. Research findings take time to translate into clinical practice, and your doctor is best placed to advise on what applies to you.
With thanks to Professor Justin Stebbing for his insights and research.